Printer Friendly - Click printer icon on browser toolbar or click file and then print
| Table 1. Drugs that impair neuromuscular transmission and may increase weakness in patients with underlying neuromuscular junction disorders Antibiotics Aminoglycosides tobramycin gentamicin netilmicin neomycin streptomycin kanamycin Fluoroquinolones ciprofloxacin norfloxacin ofloxacin Ketolides telithromycin (Ketek) Other antibiotics tetracyclines sulfonamides penicillins amino acid antibiotics macrolides azithromycin clarithromycin Table 2. Drugs implicated as potentially harmful in myasthenia gravis patients based on either anecdotal case reports or in-vitro microelectrode studies (or both) Beta blockers propranolol oxprenolol timolol practolol atenolol labetalol metoprolol nadolol |
Calcium channel blockers verapamil Other cardiac drugs procainamide bretylium trimethaphan Anticonvulsant medication phenytoin barbiturates ethosuximide carbamazepine gabapentin Ophthalmologic medications timolol betaxolol hydrochloride. echothiophate (a long-acting cholinesterase inhibitor used in the treatment of open angle glaucoma) Psychiatric drugs lithium carbonate phenothiazines amitriptyline imipramine amphetamines haloperidol Other drugs prescribed by neurologists riluzole glatiramer acetate Miscellaneous Drugs fludarabine cisplatin interleukin-2 |
|||